olysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through
a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin
dihydrochloride) Tablets, a product for the treatment of phenylketonuria
(PKU), developed in partnership with Merck Serono, a division of Merck KGaA
of Darmstadt, Germany. Other product candidates include 6R-BH4 for
cardiovascular indications, which is currently in Phase 2 clinical
development for the treatment of peripheral arterial disease and sickle
cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia
lyase), which is currently in Phase 1 clinical development for the
treatment of PKU. For additional information, please visit
http://www.BMRN.com. Information on BioMarin's website is not incorporated
by reference into this press release.
About Merck Serono
Merck Serono is the division for innovative prescription
pharmaceuticals of Merck, a global pharmaceutical and chemical group.
Headquartered in Geneva, Switzerland, Merck Serono discovers, develops,
manufactures and markets innovative small molecules and biopharmaceuticals
to help patients with unmet medical needs. Its North American business
operates in the United States and Canada as EMD Serono.
Merck Serono has leading brands serving patients with cancer
(Erbitux(R)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)),
endocrine and cardiometabolic disorders (Glucophage(R), Concor(R),
Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)).
With an annual R&D expenditure of around euro 1bn, Merck Serono is
committed to growing its business in specialist-focused therapeutic areas
including neurodegenerative diseases, oncology, fertility and
endocrinology, as well as new areas potentially arising out of research and
development in aut
'/>"/>
SOURCE BioMarin Pharmaceutical Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics2.
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan3.
Corgenix Receives Third U.S. Patent on AtherOx(R) Technology4.
Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets5.
U.S. Genomics Inc. Receives $4.5 Million Investment from BD6.
AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)7.
PLC Systems Receives Delisting Notice From American Stock Exchange8.
Nephros Receives Non-Compliance Notification from AMEX9.
China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII10.
Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules11.
Intact Medical Corporations Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA